Clinical study on the combination of Bupi Xiaoji oral liquid and basic treatment for pediatric mesenteric lymphadenitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072910

Enrollment

Unknown

Registered

2023-06-28

Start date

2023-06-30

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric mesenteric lymphadenitis

Interventions

Test group:Oral Bupi Xiaoji Oral Liquid Combined with Basic Treatment

control group: Basic treatment

Eligibility

Sex/Gender

All

Age

3 Years to 14 Years

Inclusion criteria

Inclusion criteria: Meets the diagnostic criteria of Western medicine for pediatric mesenteric lymphadenitis; Meets the diagnostic criteria of traditional Chinese medicine for pediatric abdominal pain; Meets the traditional Chinese medicine syndrome differentiation standards for milk food retention syndrome; Age range from 3 to 14 years (inclusive), regardless of gender; Abdominal pain score = 6; Children or family members can understand and cooperate in abdominal pain scoring; The child and their family agree and sign an informed consent form.

Exclusion criteria

Exclusion criteria: Patients with surgical indications; Patients with abdominal diseases caused by surgical acute abdomen, appendicitis, lymphoma, intestinal worms, and other gastrointestinal diseases; Patients with severe liver and kidney dysfunction: alanine transaminase (ALT) or aspartate transaminase (AST)>2.0 × Upper limit of normal value (ULN), and/or other known liver diseases such as acute and chronic hepatitis, cirrhosis, etc; Serum creatinine>2.0 × ULN, and/or known severe renal insufficiency. Severe primary diseases with concomitant heart, lung, brain, and hematopoietic systems; Individuals with allergic constitution or known allergies to this drug or its components; Having intellectual or mental disabilities; Those who have participated in other clinical trials within three months or are currently participating in other clinical trials; Other situations that the researcher deems unsuitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
The proportion of patients with a 50% decrease in abdominal pain score after 30 minutes of randomization;Time of disappearance of abdominal pain;Efficacy of abdominal pain score;	—

Secondary

Measure	Time frame
Traditional Chinese Medicine Syndrome Curative Effect;Single symptom efficacy;	—

Countries

The People's Republic of China

Contacts

Public ContactMa Jing

The First Affiliated Hospital of Air Force Military Medical University

jingma@fmmu.edu.cn+86 130 9690 9166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026